8-K: Precigen Prioritizes Lead Gene Therapy Program, Raises $31.4 Million in Public Offering

Precigen announced a strategic reprioritization to focus on its PRGN-2012 gene therapy program for RRP, alongside a $31.4 million capital raise.

Summary

• Precigen has strategically reprioritized its pipeline to focus on PRGN-2012, a gene therapy for recurrent respiratory papillomatosis (RRP).
• The company raised approximately $31.4 million through a public offering of common stock.
• A rolling Biologics License Application (BLA) for PRGN-2012 is anticipated in the second half of 2024 under an accelerated approval pathway.
• Enrollment has begun in the confirmatory clinical trial for PRGN-2012.
• The company has reduced its workforce by over 20% as part of the reprioritization.
• Second quarter net loss was $58.8 million, or $(0.23) per share, compared to a net loss of $20.3 million, or $(0.08) per share, in the same period last year.
• First half net loss was $82.5 million, or $(0.33) per share, compared to a net loss of $43.1 million, or $(0.18) per share, in the same period last year.
• The company has initiated the shutdown of its ActoBio subsidiary, resulting in $34.5 million in impairment charges.
• Research and development expenses increased by $3.8 million in the second quarter and $5.9 million in the first half of 2024 compared to the same periods in 2023.
• Total revenues decreased by $1.1 million in the second quarter and $1.9 million in the first half of 2024 compared to the same periods in 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the clinical data for PRGN-2012 is promising and the company has secured funding, the significant financial losses and strategic reprioritization, including workforce reductions, temper the overall sentiment. The focus on a lead program is positive, but the financial challenges and program pauses are concerning.

Positives

• PRGN-2012 demonstrated strong efficacy in the pivotal study, with 51% of patients achieving a complete response and 86% experiencing a reduction in surgical interventions.
• The company has secured $31.4 million in funding through a public offering, strengthening its financial position.
• The rolling BLA submission for PRGN-2012 is anticipated in the second half of 2024, potentially leading to accelerated approval.
• The company has initiated enrollment in the confirmatory clinical trial for PRGN-2012, a key step towards commercialization.
• The strategic reprioritization and streamlining of resources will allow the company to focus on its most promising program.

Negatives

• The company reported a significant net loss of $58.8 million in the second quarter and $82.5 million in the first half of 2024.
• Total revenues decreased by 59% in the second quarter and 51% in the first half of 2024 compared to the same periods in 2023.
• The company incurred $34.5 million in impairment charges related to the shutdown of its ActoBio subsidiary.
• The company has reduced its workforce by over 20%, which may impact morale and productivity.
• The company has paused several clinical and preclinical programs to focus on PRGN-2012.

Risks

• The company's financial losses are significant and may require further capital raises.
• The strategic reprioritization and workforce reduction may impact the development of other programs.
• The success of PRGN-2012 is critical for the company's future, and any setbacks could have a major impact.
• The company is reliant on the FDA's accelerated approval pathway for PRGN-2012, which is not guaranteed.
• The company is exploring non-dilutive financing opportunities, but there is no guarantee that these will be successful.

Future Outlook

The company expects the recent reprioritization and public offering to fund operations into early 2025, focusing on the advancement of PRGN-2012 and exploring non-dilutive financing opportunities. A potential commercial launch of PRGN-2012 is anticipated in 2025.

Management Comments

• We are all in on PRGN-2012 given the immense unmet need for RRP patients and our groundbreaking pivotal data supporting the potential of what we hope to be the first-ever FDA approved therapy to treat RRP, said Helen Sabzevari, PhD, President and CEO of Precigen.
• By strategically focusing our portfolio, streamlining resources and recent public offering, we have optimized the company to rapidly prepare for submission of a rolling biologics license application under an accelerated approval pathway.
• We are excited to have initiated enrollment in the confirmatory clinical trial and will continue to accelerate our commercial readiness campaign for a potential launch in 2025 under the leadership of our newly hired Chief Commercial Officer.
• Additionally, we plan to maximize portfolio value by focusing on strategic partnerships to further advance our highly promising UltraCAR-T programs.
• Our recent reprioritization and public offering is expected to fund our operations into early 2025 allowing us to focus on advancement of PRGN-2012 while continuing to explore potential non-dilutive financing opportunities for future liquidity, said Harry Thomasian Jr., CFO of Precigen.

Industry Context

The focus on PRGN-2012 aligns with the growing interest in gene therapies for rare diseases. The company's strategic shift reflects a trend in the biotech industry to prioritize lead programs with strong clinical data and commercial potential. The company is also looking to partner its UltraCAR-T programs which is a common strategy in the industry to share risk and development costs.

Comparison to Industry Standards

• The 51% complete response rate for PRGN-2012 is a strong result compared to other treatments for RRP, which often involve repeated surgeries.
• The company's decision to focus on a lead program and seek accelerated approval is a common strategy for biotech companies with promising therapies.
• The $31.4 million capital raise is relatively small compared to other biotech companies, but it is sufficient to fund operations into early 2025.
• The company's net losses are significant, but this is not uncommon for clinical-stage biotech companies that are investing heavily in research and development.
• The strategic reprioritization and workforce reduction are similar to actions taken by other biotech companies facing financial challenges.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the significant net losses and the impact of the strategic reprioritization.
• Employees have been impacted by the workforce reduction of over 20%.
• Patients with RRP may benefit from the potential approval of PRGN-2012.
• Suppliers and partners may be affected by the changes in the company's pipeline and operations.
• Creditors may be concerned about the company's financial losses and future funding needs.

Next Steps

• The company will submit a rolling BLA for PRGN-2012 in the second half of 2024.
• The company will continue enrollment in the confirmatory clinical trial for PRGN-2012.
• The company will focus on strategic partnerships to advance its UltraCAR-T programs.
• The company will explore non-dilutive financing opportunities for future liquidity.

Key Dates

Keywords

PRGN-2012, gene therapy, recurrent respiratory papillomatosis, RRP, biologics license application, BLA, clinical trial, public offering, strategic prioritization, ActoBio, FDA, immuno-oncology, UltraCAR-T